Table 1.
Baseline characteristics
| Vaccine at 1 × 1011 vp (n=253) | Vaccine at 5 × 1010 vp (n=129) | Placebo (n=126) | ||
|---|---|---|---|---|
| Age, years | ||||
| 18–44 | 152 (60%) | 80 (62%) | 77 (61%) | |
| 45–54 | 67 (26%) | 32 (25%) | 35 (28%) | |
| ≥55 | 34 (13%) | 17 (13%) | 14 (11%) | |
| Mean | 40·0 (12·8) | 39·7 (12·1) | 39·2 (12·5) | |
| Sex | ||||
| Male | 126 (50%) | 64 (50%) | 64 (51%) | |
| Female | 127 (50%) | 65 (50%) | 62 (49%) | |
| Body-mass index, kg/m2 | 24·2 (2·8) | 24·2 (2·7) | 23·3 (2·6) | |
| Underlying diseases | ||||
| Yes | 8 (3%) | 8 (6%) | 6 (5%) | |
| No | 245 (97%) | 121 (94%) | 120 (95%) | |
| Pre-existing adenovirus type-5 neutralising antibody | ||||
| ≤1:200, titre | 127 (50%) | 54 (42%) | 61 (48%) | |
| >1:200, titre | 126 (50%) | 75 (58%) | 65 (52%) | |
Data are number of participants (%) or mean (SD). vp=viral particles.